EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata

    July 2022 in “Value in Health
    Christian Fenske, Katherine Rosettie, T Lu, C. Ferrufino, M. Borns, Nameirakpam Johnson, Peter Morrow
    TLDR Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
    The study "EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata" conducted a budget impact analysis to estimate the financial implications of adding Baricitinib, an oral Janus kinase inhibitor, to a commercial formulary for treating severe Alopecia Areata (AA). The analysis was based on a hypothetical plan of one million lives, with the number of patients with severe AA eligible for Baricitinib estimated. The study assumed an equi-proportional adoption of Baricitinib, with its uptake increasing from 0.7% to 3.0% over a 5-year period. The net 5-year budget impact was found to be $1,383,345, which is an 11.7% budget increase, or $0.023 per member per month. The study concluded that the addition of Baricitinib to a formulary is expected to have a negligible impact on a commercial plan’s budget.
    View this study on valueinhealthjournal.com →

    Related